skip to content

Contract Wins and Joint Ventures

Vectura signs exclusive agreement with Dynavax

16 August 2017 08:04

Inhaled airways products specialist Vectura has signed an exclusive global agreement with Dynavax Technologies for the clinical application of Vectura's smart nebuliser technology to deliver Dynavax's investigational immunotherapeutic agent to lung cancer patients.

Vectura's AKITA smart nebuliser will be used by Dynavax to deliver DV281, a novel Toll-Like Receptor 9 (TLR9) agonist designed specifically for local delivery to primary lung tumours and lung metastases in order to generate an anti-tumour immune response.

Vectura's FAVORITE nebulisation technology combines optimising patient's inhalation technique with the effective control of the flow rate and volume of the drug being delivered. This approach maximises the efficiency of the nebulisation and enables consistent targeted drug deposition.

The AKITA device will initially be used in the development programme with a plan to move to the FOX handheld device as a next step.

The agreement covers the Phase I and Phase II development programmes and Vectura will provide devices and device related support to Dynavax which is responsible for the rest of the programme.

Vectura said it does not expect a material impact on R&D expenditure, which remains within the previous annual guidance range of £65-75m for 2017 and 2018.

At 8:04am: (LON:VEC) Vectura Group PLC share price was +2.15p at 114.65p

Story provided by

Related Company: VEC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.